Dare Bioscience Inc

Daré Bioscience said it expects top-line data for its Ovaprene contraceptive candidate in 2027 and plans to begin dispensing its DARE to PLAY Sildenafil Cream this quarter. The company launched Flora Sync LF5 in June, the first product in its DARE to RESTORE line, and reported positive interim results for Ovaprene with a Data Safety Monitoring Board recommendation to continue the study without modification. Daré expects to enroll sufficient subjects in 2026 to achieve at least 2,500 menstrual cycles of exposure in 2027, supporting the top-line data announcement. The FDA approved a protocol amendment to remove the expectation of 250 completers, though the agency continued to strongly recommend that minimum. Daré ended the quarter with approximately $12.6 million in cash and cash equivalents as of June 30, 2026, and a working capital deficit of approximately $0.2 million.

Daré Bioscience has launched a strategic collaboration with MyMenopauseRx, a specialized telehealth platform focused exclusively on menopause care. Under the collaboration, MyMenopauseRx will be featured as a menopause-specific telehealth partner for DARE to PLAY Sildenafil Cream, giving women seeking dedicated menopause care alongside arousal support access to a menopause specialist through MyMenopauseRx, with options for lifestyle counseling, bioidentical hormonal treatment and more, available by insurance or cash pay. This option sits alongside DARE to PLAY's existing telehealth questionnaire and the option to consult a woman's own provider. The collaboration is part of Daré's strategy to build a broader women's health ecosystem that connects its innovative products with education, clinical expertise and access to care. MyMenopauseRx currently serves women in 42 states, and most of its services are covered by commercial insurance.

Daré Bioscience announced that its President and CEO, Sabrina Martucci Johnson, will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET. She will provide a corporate overview highlighting the recent launch of FloraSync LF5™, the company’s strategy for building its commercial business while advancing its women’s health pipeline, and key milestones for long-term growth. The discussion will also cover the company’s approach to capital allocation, commercialization, and execution. A live question and answer session with audience participants will follow, and a webcast replay will be available on the company’s website for 90 days.